Webinar: Clinical value of cystatin C in drug dosing

Clinical value of predicting renal elimination of medications with cystatin C

Welcome to the fourth webinar in Gentian's cystatin C webinar series. Our US Product Specialist, Shanyil Wickramasinghe, will focus on two real-world scenarios to illustrate the clinical value of incorporating cystatin C testing into medication dosing and monitoring protocols:

• Personalisingchemotherapeutic interventions through co-reporting of cystatin C and creatinine-based eGFRs

• Cystatin C-guided dosing of vancomycin: A novel approach to achieving trough concentrations among ICU patients

Data presented in this webinar is collected from publications of independent research^1-10.

Watch the webinar here:

Contact Gentian - Cystatin C

Get in touch with our Product Manager for cystatin C for product specification and pricing:

References:

1. McMahon, BA and MH Rosner.GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease andCancer, in Kidney360, 2020.1: p. 141-150.
2. Santos, MLC et al.Nephrotoxicity in cancer treatment: Anoverview, in World J Clin Oncol, 2020.11(4): p. 190-204.
3. Orth, M et al.Avoiding Insufficient Therapies and Overdosing with Co-Reporting eGFRs for Personalized Drug Therapy and Improved Outcomes, in ACHIEVING MEASURABLY BETTER HEALTHCARE PERFORMANCE, 2019.
4. Frazee, EN et al.Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohortstudy, in Crit Care, 2014.18(3): p. R110.
5. Begg, EJ, ML Barclay and CJ Kirkpatrick.The therapeutic monitoring of antimicrobial agents, in Br J Clin Pharmacol, 1999.47(1): p. 23-30.
6. Levine, DP.Vancomycin: a history, in Clin Infect Dis, 2006.42Suppl1: p. S5-12.
7. FDA,Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing, DHHS, Editor. 2020:www.fda.gov.
8. Frazee, E et al.Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project, in Am J Kidney Dis, 2017.69(5): p. 658-666.
9. Kullar, R et al.Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort, in Pharmacotherapy, 2012.32(3): p. 195-201.
10. Lloyd-Smith, P et al.Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length ofstay, inJ Hosp Infect, 2013.85(1): p. 54-9